Tangen Biosciences has won a contract with the New York State Department of Health's Wadsworth Center, a large public health laboratory, to develop a rapid skin swab test for the treatment-resistant fungus Candida auris.
The C. auris test will run on the company's TangenDx platform, which includes an assay kit and the company's GeneSpark analyzer. Tangen currently markets rapid tests for bloodstream Candida infections, bacterial infections, and antimicrobial resistance. It plans to file an emergency use authorization for a point-of-care COVID-19 test with the U.S. Food and Drug Administration this summer.
